Study

EORTC-55092-GCG

Phase IB-II, open label, multicentre feasibility study of Pazopanib in combination with Paclitaxel and Carboplatin in patients with platinum-refractory/resistant ovarian, fallopian tube or peritoneal carcinoma.

Study documentation Back to result

Trial Status

LT-FU ongoing

Dates

Date of activation: 20-Jul-2012
Date Step1 close: 16-May-2018

Data management at EORTC

Yes

Design

Phase 1-2
Randomized open label

Targeted Sample size

EORTC Groups: 88 - All Groups: 88

Treatment

Drug
Bevacizumab, Carboplatin, Paclitaxel, Pazopanib

Study Staff

  • Ellen Peeters (Senior Clinical Operations Manager), EORTC Headquarters, Brussels
  • Sara Meloen (Pharmacovigilance Manager), EORTC Headquarters, Brussels
  • Jelle Stans (Regulatory Affairs Manager), EORTC Headquarters, Brussels
  • Corneel Coens (Lead Statistician), EORTC Headquarters, Brussels

Type of cancer

  • Ovarian
  • Fallopian Tube

Participating groups

  • EORTC Gynecological Cancer Group

Recruiting centers

  • C.H.U. Sart-Tilman (Liege, Belgium)
  • Centre Hospitalier Regional De La Citadelle (Liege, Belgium)
  • Erasmus MC Hospital (Rotterdam, Netherlands)
  • Hospital Universitario 12 De Octubre (Madrid, Spain)
  • Hospital Universitario San Carlos (Madrid, Spain)
  • Institut Jules Bordet (Anderlecht, Belgium)
  • Radboud University Medical Center Nijmegen (Nijmegen, Netherlands)

Protocol summary

http://clinicaltrials.gov/study/NCT01402271

NCT number

NCT01402271

EudraCT

2010-024077-39